Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Meperizumab vs NUCALA in Healthy Male Volunteers
NCT05353179Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jun 2022
- Primary completion
- Oct 2022
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of meperizumab in eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES) (2 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Peak Concentration and Area Under Drug Concentration-Time Curve (0-t). Status: unknown.
02
Drugs
meperizumab
03
Conditions
eosinophilic granulomatosis with polyangiitis (EGPA)hypereosinophilic syndrome (HES)
Beyond the preview
Go deeper on NCT05353179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05353179.